Submit Manuscript  

Article Details


What is the Role of Cangrelor in Patients Undergoing PCI?

Author(s):

Michal Droppa and Tobias Geisler*   Pages 1 - 6 ( 6 )

Abstract:


Dual antiplatelet therapy with aspirin and oral P2Y12-receptor inhibitors prevents ischemic events in patients undergoing percutaneous coronary intervention (PCI). However oral administration of antiplatelet drugs cause delay of onset of platelet inhibition in P2Y12-inhibitor naïve patients. Cangrelor is a novel P2Y12-receptor inhibitor which is administrated intravenously and thus allows immediate antiplatelet inhibition during PCI. Due to its unique pharmacokinetics with fast onset of platelet inhibition and very short plasma half-life it allows effective and controllable periprocedural platelet inhibition. It could reduce short-term ischemic events in large randomized clinical trials. The present article reviews the available evidence and application on cangrelor use in clinical practice.

Keywords:

cangrelor, P2Y12-receptor inhibitors, platelet inhibition, coronary artery disease, acute coronary syndrome, percutaneous coronary intervention

Affiliation:

Department of Cardiology and Cardiovascular Medicine, University Hospital of Tubingen, Tubingen, Department of Cardiology and Cardiovascular Medicine, University Hospital of Tubingen, Tubingen



Read Full-Text article